Colorectal cancer surveillance in inflammatory bowel disease: The search continues

被引:46
作者
Ahmadi, Anis [1 ]
Polyak, Steven [1 ]
Draganciv, Peter V. [1 ]
机构
[1] Univ Florida, Dept Gastroenterol Hepatol & Nutr, Gainesville, FL 32610 USA
关键词
Colorectal cancer; Crohn's disease; Inflammatory bowel disease; Surveillance colonoscopy; Ulcerative colitis; PRIMARY SCLEROSING CHOLANGITIS; LOW-GRADE DYSPLASIA; POPULATION-BASED COHORT; ULCERATIVE-COLITIS; RISK-FACTOR; CROHNS-DISEASE; FOLLOW-UP; INTRAEPITHELIAL NEOPLASIA; INTESTINAL CANCER; CHROMOENDOSCOPY;
D O I
10.3748/wjg.15.61
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients with inflammatory bowel disease (IBD) are at increased risk for colorectal cancer (CRC). Risk factors for the development of CRC in the setting of IBD include disease duration, anatomic extent of disease, age at time of diagnosis, severity of inflammation, family history of colon cancer, and concomitant primary sclerosing cholangitis. The current surveillance strategy of surveillance colonoscopy with multiple random biopsies most likely reduces morbidity and mortality associated with IBD-related CRC. Unfortunately, surveillance colonoscopy also has severe limitations including high cost, sampling error at time of biopsy, and interobserver disagreement in histologically grading dysplasia. Furthermore, once dysplasia is detected there is disagreement about its management. Advances in endoscopic imaging techniques are already underway, and may potentially aid in dysplasia detection and improve overall surveillance outcomes. Management of dysplasia depends predominantly on the degree and focality of dysplasia, with the mainstay of management involving either proctocolectomy or continued colonoscopic surveillance. Lastly, continued research into additional chemopreventive agents may increase our arsenal in attempting to reduce the incidence of IBD-associated CRC. (C) 2009 The WJG Press and Baishideng. All rights reserved.
引用
收藏
页码:61 / 66
页数:6
相关论文
共 64 条
  • [1] [Anonymous], 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000279.PUB2
  • [2] Family history as a risk factor for colorectal cancer in inflammatory bowel disease
    Askling, J
    Dickman, PW
    Karlén, P
    Broström, O
    Lapidus, A
    Löfberg, R
    Ekbom, A
    [J]. GASTROENTEROLOGY, 2001, 120 (06) : 1356 - 1362
  • [3] Bansal P, 1996, AM J GASTROENTEROL, V91, P44
  • [4] Low grade dysplasia in extensive, long-standing inflammatory bowel disease - A follow-up study
    Befrits, R
    Ljung, T
    Jaramillo, E
    Rubio, C
    [J]. DISEASES OF THE COLON & RECTUM, 2002, 45 (05) : 615 - 620
  • [5] Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer?
    Bernstein, CN
    Blanchard, JF
    Metge, C
    Yogendran, M
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (12) : 2784 - 2788
  • [6] Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO
  • [7] 2-Z
  • [8] BLACKSTONE MO, 1981, GASTROENTEROLOGY, V80, P366
  • [9] PRIMARY SCLEROSING CHOLANGITIS IN ULCERATIVE-COLITIS - A RISK FACTOR FOR THE DEVELOPMENT OF DYSPLASIA AND DNA ANEUPLOIDY
    BROOME, U
    LINDBERG, G
    LOFBERG, R
    [J]. GASTROENTEROLOGY, 1992, 102 (06) : 1877 - 1880
  • [10] NEOPLASTIC PROGRESSION IN ULCERATIVE-COLITIS - HISTOLOGY, DNA CONTENT, AND LOSS OF A P53 ALLELE
    BURMER, GC
    RABINOVITCH, PS
    HAGGITT, RC
    CRISPIN, DA
    BRENTNALL, TA
    KOLLI, VR
    STEVENS, AC
    RUBIN, CE
    [J]. GASTROENTEROLOGY, 1992, 103 (05) : 1602 - 1610